The drug was initially licensed to a company that recently filed for Chapter 7 bankruptcy. Now Colorado-based Ariel Pharmaceuticals has picked up Tamiasyn and will take over the task of preparing it for human clinical trials.
U of M president picks alum for second-in-command
Incoming VP and Provost Karen Hanson brings a background in the humanities at a time when the liberal arts are under attack. University President Eric Kaler says her education will help balance his own as an engineer. Hanson has said that making the case for the humanities "will have to be made again and again."